Heresco-Levy U - Search Results

1

Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.

Heresco-Levy U, Silipo G, Javitt DC. Heresco-Levy U, et al. Psychopharmacol Bull. 1996;32(4):731-40. Psychopharmacol Bull. 1996. PMID: 8993096 Clinical Trial.

2

[The phencyclidine-N-methyl-D-aspartate theory of schizophrenia: clinical applications].

Heresco-Levy U, Elman I, Javitt D. Heresco-Levy U, et al. Harefuah. 1994 May 15;126(10):598-601. Harefuah. 1994. PMID: 8034251 Review. Hebrew. No abstract available.

3

Amelioration of negative symptoms in schizophrenia by glycine.

Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Javitt DC, et al. Am J Psychiatry. 1994 Aug;151(8):1234-6. doi: 10.1176/ajp.151.8.1234. Am J Psychiatry. 1994. PMID: 8037263 Clinical Trial.

4

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Heresco-Levy U, et al. Br J Psychiatry. 1996 Nov;169(5):610-7. doi: 10.1192/bjp.169.5.610. Br J Psychiatry. 1996. PMID: 8932891 Clinical Trial.

5

Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.

Heresco-Levy U, Greenberg D, Lerer B, Javitt DC, Brown WA. Heresco-Levy U, et al. Isr J Psychiatry Relat Sci. 1997;34(4):281-9. Isr J Psychiatry Relat Sci. 1997. PMID: 9409085 Clinical Trial.

6

The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes.

Heresco-Levy U, Javitt DC. Heresco-Levy U, et al. Eur Neuropsychopharmacol. 1998 May;8(2):141-52. doi: 10.1016/s0924-977x(97)00050-3. Eur Neuropsychopharmacol. 1998. PMID: 9619693 Free article. Review.

7

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Heresco-Levy U, et al. Arch Gen Psychiatry. 1999 Jan;56(1):29-36. doi: 10.1001/archpsyc.56.1.29. Arch Gen Psychiatry. 1999. PMID: 9892253 Clinical Trial.

8

Treatment-resistant schizophrenia and staff rejection.

Heresco-Levy U, Ermilov M, Giltsinsky B, Lichtenstein M, Blander D. Heresco-Levy U, et al. Schizophr Bull. 1999;25(3):457-65. doi: 10.1093/oxfordjournals.schbul.a033393. Schizophr Bull. 1999. PMID: 10478781

9

Are glycine sites saturated in vivo?

Javitt DC, Heresco-Levy U. Javitt DC, et al. Arch Gen Psychiatry. 2000 Dec;57(12):1181-3. doi: 10.1001/archpsyc.57.12.1181. Arch Gen Psychiatry. 2000. PMID: 11115334 No abstract available.

10

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B. Segman RH, et al. Psychopharmacology (Berl). 2000 Nov;152(4):408-13. doi: 10.1007/s002130000521. Psychopharmacology (Berl). 2000. PMID: 11140333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters